Phosphagenics investigation
Phosphagenics (ASX: PHO) is awaiting the results of an investigation into what have been identified as “irregular transactions in relation to its invoicing and accounting records.”
Independent legal and accounting professionals are undertaking a thorough and extensive investigation. The company has said that “the amounts involved may be material.”
CEO Dr Esra Ogru has been suspended by the company’s Board of Directors pending the outcomes of the investigation.
In the interim, joint CEO Harry Rosen has returned from the Phosphagenics’s New York office.
The company confirmed it held current cash of $14.1 million and that its clinical trial programs would continue as planned.
Phosphagenics’ shares were trading at $0.11 at about 11 am today.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
